BriaCell Therapeutics Corp.
BCTX
$10.20
$0.121.19%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.76% | -21.79% | -22.94% | -20.03% | -22.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.38% | -30.76% | -13.86% | 13.68% | 43.22% |
| Operating Income | 18.38% | 30.76% | 13.86% | -13.68% | -43.22% |
| Income Before Tax | -438.49% | -221.90% | 7.61% | -26.31% | 75.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -438.49% | -221.90% | 7.61% | -26.31% | 75.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 74.30% | 95.36% | 60.49% | 191.57% | -- |
| Net Income | -449.14% | -224.13% | 8.05% | -25.77% | 76.40% |
| EBIT | 18.38% | 30.76% | 13.86% | -13.68% | -43.22% |
| EBITDA | 18.49% | 31.16% | 14.23% | -13.34% | -42.95% |
| EPS Basic | -86.45% | -46.50% | 58.21% | -3.22% | 77.63% |
| Normalized Basic EPS | -89.00% | -47.12% | 58.47% | -2.93% | 78.02% |
| EPS Diluted | 53.06% | 55.80% | 79.97% | 49.03% | 11.53% |
| Normalized Diluted EPS | -79.20% | -41.16% | 59.27% | -1.08% | 76.82% |
| Average Basic Shares Outstanding | 287.12% | 120.91% | 59.29% | 21.47% | 5.28% |
| Average Diluted Shares Outstanding | 283.02% | 118.49% | 57.53% | 20.12% | 6.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |